I-Pfizer ifuna ugunyaziso losetyenziso olungxamisekileyo kwi-FDA yenoveli yayo ye-Covid-19 ipilisi ye-antiviral Paxlovid.
Yabelana ngenqaku
Kwizithende zokwamkelwa kweMerck antiviral molnupiravir yase-UK, uPfizer uzimisele ukufumana ipilisi yakhe ye-Covid-19, iPaxlovid, kwintengiso.Kule veki, umenzi weziyobisi wase-US ufune ugunyaziso losetyenziso olungxamisekileyo kwi-US Food and Drug Administration (FDA) kumgqatswa wayo omtsha we-antiviral kubantu abane-Covid-19 ephakathi ukuya kwe-19, abasengozini enkulu yokulaliswa esibhedlele okanye yokusweleka. iqalise inkqubo yokufuna imvume yokulawula kwamanye amazwe aquka i-UK, i-Australia, iNew Zealand kunye ne-South Korea, kwaye iceba ukufaka izicelo ezongezelelweyo.Isebenza njani i-Paxlovid?I-Paxlovid yindibaniselwano ye-Pfizer yophando ye-antiviral PF-07321332 kunye nedosi ephantsi i-ritonavir, iyeza le-antiretroviral ngokwesiqhelo elisetyenziselwa ukunyanga i-HIV.Unyango luphazamisa ukuphindaphindwa kwe-SARS-CoV-2 emzimbeni ngokuzibophelela kwi-3CL-efana ne-protease, i-enzyme ebalulekileyo ekusebenzeni kwentsholongwane kunye nokuzala.
Ngokohlalutyo lwexeshana, u-Paxlovid wehlise umngcipheko wokulaliswa esibhedlele ezinxulumene ne-Covid-19 okanye ukusweleka ngama-89% kwabo bafumana unyango kwiintsuku ezintathu zokuqala kweempawu.Ichiza lafunyaniswa lisebenza kakhulu-i-1% kuphela yezigulane ezafumana i-Paxlovid zalaliswa esibhedlele ngosuku lwama-28 xa kuthelekiswa ne-6.7% yabathathi-nxaxheba be-placebo-ukuba ulingo lwalo lweSigaba II/III lwapheliswa kwangoko kwaye ukungeniswa okusemthethweni kwi-FDA kwafakwa ngokukhawuleza kunokuba kulindeleke.Ngaphezu koko, ngelixa ukufa kwe-10 kuchazwe kwingalo ye-placebo, akukho nanye eyenzeka phakathi kwabathathi-nxaxheba abafumana i-Paxlovid.Njenge-molnupiravir, i-Paxlovid ilawulwa ngomlomo, okuthetha ukuba abaguli be-Covid-19 banokuthatha iyeza ekhaya kumanqanaba okuqala osulelo.Ithemba lelokuba ii-antivirals ezintsha ezifana nezo zivela kwi-Merck kunye ne-Pfizer ziya kuvumela abantu abaneemeko ezithambileyo okanye ezilinganiselweyo ze-coronavirus ukuba banyangwe kwakamsinya, kuthintelwe ukuqhubeka kwesifo kunye nokunceda ukuthintela ukuba izibhedlele zingonganyelwa.
Ukhuphiswano lwamachiza e-Covid-19 iMerck's molnupiravir, ipilisi yokuqala eyamkelweyo ye-Covid-19, iye yachazwa njengokutshintsha umdlalo ukusukela oko uphononongo lufumanise ukuba yehlisile ukulaliswa esibhedlele kunye nomngcipheko wokubhubha ngama-50%.Kodwa oko akuthethi ukuba umnikelo we-antiviral wePfizer awuyi kuba nomphetho kwintengiso.Uhlalutyo lwexeshana lokusebenza kwe-molnupiravir luyathembisa, kodwa ukuncitshiswa komngcipheko okumangalisayo okuxelwe nguPfizer kubonisa ukuba ipilisi yayo inokungqina isixhobo esixabisekileyo kwindawo yezixhobo zikarhulumente ngokuchasene nobhubhane. i-antiviral ephikisanayo.Ezinye iingcali zivakalise inkxalabo yokuba indlela yokusebenza ye-molnupiravir ngokuchasene ne-Covid-19- ilinganisa iimolekyuli ze-RNA ukukhuthaza utshintsho lwentsholongwane- inokwazisa utshintsho oluyingozi kwi-DNA yomntu.I-Paxlovid, uhlobo olwahlukileyo lwe-antiviral eyaziwa ngokuba yi-protease inhibitor, aluzange lubonise iimpawu "ze-mutagenic DNA interactions", utshilo uPfizer.
Ixesha lokuposa: Nov-19-2021